<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="857">
  <stage>Registered</stage>
  <submitdate>26/10/2005</submitdate>
  <approvaldate>18/11/2005</approvaldate>
  <actrnumber>ACTRN12605000758606</actrnumber>
  <trial_identification>
    <studytitle>CardioFit(TM) for heart Failure</studytitle>
    <scientifictitle>A non randomized trial to evaluate the safety and efficacy of the CardioFit â¿¢ implantable neurostimulator for the treatment of patients diagnosed with NYHA Class II-IV heart failure disease to improve cardiac haemodynamic makers such as left ventricular ejection fraction, stroke volume and prevent the negative left ventricular remodeling seen in patients with a congestive cardiomyopathy.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>NYHF II-IV Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A non randomized study for the Cardiofit â¿¢ system, involving implantation of active neurostimulator for vagal stimulation. The surgical procedure will take approximately an hour and will be conducted under general anesthesia. Overall study duration is estimated at 18 months, consists of 12 months recruitment time. Nevertheless, patients will be followed up to 3 years post implantation in 6 months interval.</interventions>
    <comparator />
    <control>Historical</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of all adverse events</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary outcome will measure the CardiFit (TM) efficacy according to the listed parameters: NYHA functional class; QoL, Exercise capacity;Oxegen consumption; Ejection fraction; Circulating cytokines.</outcome>
      <timepoint>Outcome measurements will take place at each follow up visit at 1,2,3,4,5 and 6 months post parameter setting of the system.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. NYHA II-IV2. Resting HR&gt;70 and HR&lt;1303. EF&lt;35%4. Patient capable to perfom walking test.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Life threatening condition2. Acute MI3. Cerebral vascular accident4. CABG or PTCA in the last 3 months5. Acute myocarditis6. Constrictive pericarditis, aortic stenosis 7.Acure reanl of hepatic failure8. Anatomical defect that preclude use of device9.Hypotension10. Mitral stenosis11.Active peptic disease12. Asthma, severe COPD13. AV block of 1-3 degree14. Atrial fibrilation15. Long QT syndrome16. Glaucoma17. immunosuppressed patients18. LBBB.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/11/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioControl Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Israel</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Harry Mond</name>
      <address>Cardiology Department
Royal Melbourne Hospital
City Campus
Grattan St
Parkville VIC 3050</address>
      <phone>+61 3 93427133 ext.7076</phone>
      <fax />
      <email>hmond@bigpond.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shirley Giorini-Silfen</name>
      <address>7 Vernon St
Glen Iris VIC 3146</address>
      <phone>+61 3 98860335</phone>
      <fax />
      <email>rsilfen@bigpond.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>